Coherus Oncology, Inc.
CHRS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001512762
No open-market purchases or sales by Coherus Oncology, Inc. insiders were filed in the last 90 days; 146 institutions reported holding it in 13F filings for Q2 2026, worth $98.5M in total; no superinvestor holds it.
Q1 2022 vs. Q4 2021
How the institutions holding Coherus Oncology, Inc. changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Q1 2022 | Change |
|---|---|---|---|
| Holders | 201 | 184 | −17 |
| Shares | 76.8M | 76.0M | −781.4K (−1.0%) |
| Value | $1.23B | $980.7M | −$246.5M (−20.1%) |
New holders (21)
Institutions that held Coherus Oncology, Inc. at the end of Q1 2022 but not at the end of Q4 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Two Sigma Advisers, LP | 76,600 | $989.0K | 0.00% |
| Connor, Clark & Lunn Investment Management Ltd. | 63,791 | $824.0K | 0.00% |
| Engineers Gate Manager LP | 35,240 | $455.0K | 0.02% |
| HSBC Holdings PLC | 34,153 | $449.0K | 0.00% |
| Amalgamated Financial Corp. | 31,287 | $404.0K | 0.00% |
| Atom Investors LP | 30,502 | $394.0K | 0.18% |
| Quantedge Capital Pte Ltd | 28,200 | $364.0K | 0.11% |
| Graham Capital Management, L.P. | 27,316 | $352.0K | 0.02% |
| Russell Investments Group, Ltd. | 21,500 | $277.0K | 0.00% |
| Blueshift Asset Management, LLC | 19,475 | $251.0K | 0.02% |
| E Fund Management Co., Ltd. | 13,486 | $174.0K | 0.01% |
| FDx Advisors, Inc. | 11,874 | $153.0K | 0.01% |
| Victory Capital Management Inc | 13,336 | $121.0K | 0.00% |
| Aquatic Capital Management LLC | 3,100 | $40.0K | 0.06% |
| CWM, LLC | 991 | $13.0K | 0.00% |
| Meeder Asset Management Inc | 103 | $1.00K | 0.00% |
| Signaturefd, LLC | 81 | $1.00K | 0.00% |
| Fieldpoint Private Securities, LLC | 45 | $1.00K | 0.00% |
| Lindbrook Capital, LLC | 63 | $1.00K | 0.00% |
| Global Retirement Partners, LLC | 32 | $0 | 0.00% |
| TCWP LLC | 59 | $0 | 0.00% |
Sold out (38)
Institutions that held Coherus Oncology, Inc. at the end of Q4 2021 and filed for Q1 2022 without it.